Search hospitals
>
Illinois
>
Chicago
University of Chicago Comprehensive Cancer Center
Claim this profile
Chicago, Illinois 60637
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Ovarian Cancer
Conducts research for Lung Cancer
Conducts research for Pancreatic Cancer
594 reported clinical trials
51 medical researchers
Summary
University of Chicago Comprehensive Cancer Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreatic Cancer and other specialties. University of Chicago Comprehensive Cancer Center is involved with conducting 594 clinical trials across 748 conditions. There are 51 research doctors associated with this hospital, such as Rita Nanda, MD, Ardaman Shergill, MD, Ami V Desai, and Christine M. Bestvina.
Area of expertise
Cancer
University of Chicago Comprehensive Cancer Center has run 104 trials for Cancer. Some of their research focus areas include:
Breast Cancer
University of Chicago Comprehensive Cancer Center has run 64 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Rita Nanda, MD
University of Chicago Comprehensive Cancer Center
8 years of reported clinical research
Ardaman Shergill, MD
University of Chicago Comprehensive Cancer Center
3 years of reported clinical research
Ami V Desai
University of Chicago Comprehensive Cancer Center
5 years of reported clinical research
Christine M. Bestvina
University of Chicago Comprehensive Cancer Center
6 years of reported clinical research
Clinical Trials running at University of Chicago Comprehensive Cancer Center
Cancer
Lung Cancer
Breast Cancer
Brain Tumor
Kidney Cancer
Pancreatic Cancer
Breast cancer
Prostate Cancer
Esophageal cancer
Testicular cancer
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting
2 awards
Phase 3
26 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting
2 awards
Phase 3
12 criteria
Cetuximab + Pembrolizumab
for Head and Neck Cancer
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.
Recruiting
2 awards
Phase 3
16 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Chicago Comprehensive Cancer Center?
University of Chicago Comprehensive Cancer Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreatic Cancer and other specialties. University of Chicago Comprehensive Cancer Center is involved with conducting 594 clinical trials across 748 conditions. There are 51 research doctors associated with this hospital, such as Rita Nanda, MD, Ardaman Shergill, MD, Ami V Desai, and Christine M. Bestvina.
Where is University of Chicago Comprehensive Cancer Center located?
**Directions to the Center for Care and Discovery:** - From the north, take the Kennedy Expressway (I-90) east or Edens Expressway (I-94) south. - Merge onto the Dan Ryan Expressway (I-90/94) east. - Exit at 55th Street (Garfield Boulevard) and follow signs to 5700 S. Maryland Ave.
Who should I call to ask about financial aid or insurance network?
For insurance inquiries at the University of Chicago Comprehensive Cancer Center, email Benefits@uchicago.edu or call 773-702-9634. For financial assistance, download the application in English or Spanish, attach supporting documents, and mail to The University of Chicago Medicine, 150 Harvester Dr., Ste 300, Burr Ridge, IL 60527-5965. For billing questions, contact (773) 702-6664 or send mail to the same address.
What insurance does University of Chicago Comprehensive Cancer Center accept?
The University of Chicago Comprehensive Cancer Center accepts a broad spectrum of insurance plans, such as Aetna, AIG Medical, American Health Holding, Blue Cross Blue Shield PPO, Cigna, Coventry Health Care of Illinois (PersonalCare) HMO, Health Alliance PPO, Humana, Medicaid (Illinois), Medicare, MultiPlan PPO, and United Healthcare Choice Plus (POS/PPO). This includes commercial insurance plans, exchange or health insurance marketplace plans, and Medicare and Medicare Advantage insurance plans. Please contact your insurance company to confirm coverage before receiving services.
What awards or recognition has University of Chicago Comprehensive Cancer Center received?
The University of Chicago Comprehensive Cancer Center (UCCCC) has been an NCI-Designated Cancer Center since 1973 and achieved comprehensive status in 2008. It is renowned for its contributions to basic and clinical research, especially in drug development and early-phase clinical trials, enrolling about 1,000 patients annually. The center excels in genetic classification of hematological malignancies, cancer immunology, pharmacogenomics, and cancer genetics, among other areas, and has earned significant accolades including the Leapfrog Group's Top Teaching Hospital and the Magnet Recognition Program designation.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.